Sale disclosed
Melissa B. Epperly
Director
Common Shares
- Reported value
- $607.95K
- Reported price
- $36.08 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Roivant Sciences Ltd.
Last 30 daysNo qualifying insider buying. Sales: $9.16M by 3 insiders.
Showing the first 6 of 20 trades on this page.
Director
Common Shares
Director
Common Shares
President & Immunovant CEO
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & CIO
Common Shares
President & Immunovant CEO
Common Shares
Director
Common Shares
Director
Common Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common SharesSale10b5-12 trades | 17,750avg $36.10 / share | $640.86K | Oct 1Filed Oct 5 · 4d later | 2 filings
|
| President & Immunovant CEO | Common SharesSale10b5-1 | 200,000$36.62 / share | $7.32M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| Director | Common SharesSale10b5-12 trades | 4,938avg $39.74 / share | $196.23K | Sep 15Filed Sep 17 · 2d later | 2 filings
|
| Director | Common SharesSale10b5-12 trades | 5,112avg $39.74 / share | $203.15K | Sep 15Filed Sep 17 · 2d later | 2 filings
|
| Director | Common SharesSale10b5-1 | 20,000$39.90 / share | $798K | Sep 8Filed Sep 10 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesSale10b5-12 trades | 200,000avg $35.77 / share | $7.15M | Aug 28Filed Sep 1 · 4d later | 2 filings
|
| President & CIO | Common SharesSale | 172,899$37.17 / share | $6.43M | Aug 19Filed Aug 21 · 2d later | SEC filing |
| President & CIO | Common SharesSale | 17,519$37.30 / share | $653.46K | Aug 20Filed Aug 21 · 1d later | SEC filing |
| President & CIO | Common SharesSale | 144,756$36.48 / share | $5.28M | Aug 21Filed Aug 21 · 0d later | SEC filing |
| President & CIO | Common SharesSale | 243,177$36.23 / share | $8.81M | Aug 14Filed Aug 18 · 4d later | SEC filing |
| President & CIO | Common SharesSale | 284,707$36.25 / share | $10.32M | Aug 17Filed Aug 18 · 1d later | SEC filing |
| President & CIO | Common SharesSale2 trades | 136,942avg $36.73 / share | $5.03M | Aug 18Filed Aug 18 · 0d later | 2 filings
|
| President & Immunovant CEO | Common SharesSale10b5-1 | 200,000$34.95 / share | $6.99M | Jul 27Filed Jul 29 · 2d later | SEC filing |
| Director | Common SharesSale10b5-1 | 10,000$34.90 / share | $349K | Jun 30Filed Jul 2 · 2d later | SEC filing |
| Director | Common SharesSale10b5-1 | 15,002$34.32 / share | $514.87K | Jun 29Filed Jul 1 · 2d later | SEC filing |
Showing the latest 20 of 46 trades. Show all 46 trades
Roivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a sale for a spouse.
Lisa McClainReporting House memberRoivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a purchase for a spouse.
Lisa McClainReporting House memberRoivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a sale for a spouse.
Lisa McClainReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.